• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 30, 2013

View Archived Issues

Vertex Cuts 370 Jobs on Incivek Sales Drop; Hitches Wagon to CF

Vertex Pharmaceuticals Inc. faced the music on Incivek (telaprevir), slashing 370 jobs – 15 percent of its work force – after patients turned from the flagging hepatitis C virus (HCV) drug to newer therapies. Revenues from Incivek plummeted to $85.6 million in the third quarter from $254.3 million during the same period a year earlier. Read More

Presenting . . . BioWorld Asia

Not if, but when and how. That’s the conclusion most biopharmaceutical executives have today when it comes to developing a global strategy – increasingly focused on Asia. Read More

Charleston Ends Phase III Early: Opioid-Nausea Therapy Works

Although opioid-induced constipation (OIC) has gotten most of the press in recent years, Charleston Laboratories Inc. may be about to change all that, given Phase III success with CL-108, which provides the pain relief of hydrocodone without the side effects that are even more prevalent: nausea and vomiting (OINV). Read More

Global Biosimilars Name Game Continues to Heat Up

The regulatory experts who gathered in Europe from all over the world to consider a global standard for naming biosimilars got such an earful of contradictory views that they’re likely to hold at least one more public forum before they recommend an international nonproprietary naming (INN) scheme for the follow-on biologics. Read More

Series D to Boost Calithera’s Cancer Compound into Phase I

A new Series D financing round worth $35 million will support Calithera Biosciences Inc.’s Phase I study of its cancer candidate, CB-839. The compound is designed to block cancer cell growth through inhibition of glutaminase. In preclinical studies, Calithera showed potent and selective activity of CB-839 against multiple tumor types. Read More

Collaborative Study Nets 11 New Genes for Alzheimer’s Disease

LONDON – A genomewide association study of people with Alzheimer’s disease has delivered a haul of 19 regions of the genome that are significantly associated with that disease, including 11 that have been linked with Alzheimer’s for the first time. Read More

Numab Regains Asthma Bispecific Antibody Fragment from Sucampo

Early stage fragment antibody developer Numab AG has regained control of a drug development program in severe asthma it originally licensed to Sucampo Pharmaceuticals Inc. more than two years ago and is now seeking Series A funding to take forward that molecule, ND003, as well as a second drug candidate, ND007, which is in development for autoimmune indications. Read More

Other News To Note

• Pharmalink AB, of Stockholm, said Busulipo, a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation, received orphan drug designation from the FDA. Read More

Stock Movers

Read More

Clinic Roundup

• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., provided an update on the status of its Phase III trial with lead candidate Firdapse (amifampridine phosphase) for the treatment of Lambert-Eaton myasthenic syndrome. Read More

Pharma: Other News To Note

• Incelldx Inc., of Menlo Park, Calif., said it entered a deal with Bristol-Myers Squibb Co., of New York, related to the development of an assay for potential application of a molecular companion diagnostic intended to identify patients likely to benefit from treatment with a BMS drug currently in development. Read More

Pharma: Clinic Roundup

• Merck & Co. Inc., of Whitehouse Station, N.J., presented interim data from a Phase Ib trial of MK-3475, for non-small-cell lung cancer at the World Conference on Lung Cancer in Sydney. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe